K101174 is an FDA 510(k) clearance for the ATRICURE BIPOLAR SYSTEM INCLUDING ISOLATOR SYNERGY DUAL ELECTRODE CLAMPS MODE.... Classified as Surgical Device, For Cutting, Coagulation, And/or Ablation Of Tissue, Including Cardiac Tissue (product code OCL), Class II - Special Controls.
Submitted by AtriCure, Inc. (West Chester, US). The FDA issued a Cleared decision on November 12, 2010 after a review of 199 days - an extended review cycle.
This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 878.4400 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.
View all AtriCure, Inc. devices
NCT00560885
Completed
Interventional
Industry-sponsored
AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation
AtriCure Synergy Bipolar RF Energy Lesions for Permanent Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery
| Condition studied |
Atrial Fibrillation |
| Study design |
Single group |
| Eligibility |
All sexes
· 18 Years+
|
| Sponsor |
AtriCure, Inc.
(industry)
|
Started 2007-11-01
→
Primary completion 2009-12-01
→
Completed 2012-12-01
Primary outcome
Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months.
Secondary outcome
Percent of Patients Free From AF, Independent of Antiarrhythmic Drug Status as Determined by Holter Monitoring at 6 Months.
View full study on ClinicalTrials.gov